[Controversies regarding the use of 0.75% bupivacaine].
Controversies are described regarding wide introduction of bupivacaine with raised concentration (0.75%) of the active components, which has been introduced in other countries in the strongest local anaesthetic agent used as yet but in early 1980s it has been withdrawn from several western countries in view of possible serious cardiovascular side effects. Presently, after a number of studies it been demonstrated that these suppositions were unfounded and the observed complication were due errors in anaesthesiological techniques and not to an exceptional cardiotoxicity of the drug.
Knapik
P
P
Zakładu Anastezjologii i Intensywnej Terapii Górniczego Centrum Medycznego, Katowicach.
Gallert
G
G
Knapik
M
M
Antoszewski
Z
Z
D000698:Analgesia / Q000009:adverse effects / Q000379:methods*; D000767:Anesthesia, Epidural / Q000009:adverse effects / Q000379:methods*; D000772:Anesthesia, Local / Q000009:adverse effects / Q000379:methods*; D002045:Bupivacaine / Q000008:administration & dosage* / Q000494:pharmacology / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D006801:Humans; D008508:Medication Errors; D017180:Tachycardia, Ventricular / Q000139:chemically induced*
D002045:Bupivacaine
Kontrowersje wokół stosowania 0.75% bupiwakainy.